AI assistant
Sending…
RESMED INC — Director's Dealing 2023
Sep 19, 2023
30071_dirs_2023-09-19_cbe66384-6f2d-4607-81ef-7a3ff90d1a7b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2023-09-15
Reporting Person: Farrell Michael J. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-09-15 | ResMed Common Stock | M | 5675 | $57.76 | Acquired | 455035 | Direct |
| 2023-09-15 | ResMed Common Stock | S | 5675 | $146.346 | Disposed | 449360 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-09-15 | ResMed Common Stock Options | $57.76 | M | 5675 | Disposed | 2023-11-16 | ResMed Common Stock (5675) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ResMed Common Stock | 4090 | Indirect |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan adopted November 8, 2021.
F2: This transaction was executed in multiple trades at prices ranging from $145.09 to 148.07. The price reported above reflects the weighted average sale price.
F3: Options are exercisable 1/3 each year beginning 1 year from date of grant.
More from RESMED INC
Regulatory Filings
2026
May 26
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Regulatory Filings
2026
Jan 29